These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 20979952)
1. Prevalence of the antiheparin-platelet factor 4 antibody in hemodialysis (HD) patients and its effects upon dialysis access. Wallace K; Dasgupta I; Stratton J; Johnston P; Parry R Clin Nephrol; 2010 Nov; 74(5):409-10. PubMed ID: 20979952 [No Abstract] [Full Text] [Related]
2. The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis. Carrier M; Knoll GA; Kovacs MJ; Moore JC; Fergusson D; Rodger MA Thromb Res; 2007; 120(2):215-20. PubMed ID: 17098277 [TBL] [Abstract][Full Text] [Related]
3. Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia. Wanaka K; Matsuo T; Matsuo M; Kaneko C; Miyashita K; Asada R; Matsushima H; Nakajima Y J Thromb Haemost; 2010 Mar; 8(3):616-8. PubMed ID: 20050999 [No Abstract] [Full Text] [Related]
4. Role of platelet factor 4-heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis. Nakamoto H; Shimada Y; Kanno T; Wanaka K; Matsuo T; Suzuki H Hemodial Int; 2005 Oct; 9 Suppl 1():S2-7. PubMed ID: 16223438 [TBL] [Abstract][Full Text] [Related]
5. Frequency of antibodies directed against heparin-platelet factor 4 in patients exposed to heparin through chronic hemodialysis. de Sancho M; Lema MG; Amiral J; Rand J Thromb Haemost; 1996 Apr; 75(4):695-6. PubMed ID: 8743204 [No Abstract] [Full Text] [Related]
6. Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. O'Shea SI; Sands JJ; Nudo SA; Ortel TL Am J Hematol; 2002 Jan; 69(1):72-3. PubMed ID: 11835336 [TBL] [Abstract][Full Text] [Related]
7. The presence of heparin-platelet factor 4 antibodies as a marker of hypercoagulability during hemodialysis. Yu A; Jacobson SH; Bygdén A; Egberg N Clin Chem Lab Med; 2002 Jan; 40(1):21-6. PubMed ID: 11916267 [TBL] [Abstract][Full Text] [Related]
8. Heparin-independent activation of platelets by HIT antibodies: a clue to the etiology of delayed thrombocytopenia/thrombosis in patients given heparin? Aster RH J Thromb Haemost; 2005 Oct; 3(10):2166-7. PubMed ID: 16194194 [No Abstract] [Full Text] [Related]
9. Anti-heparin-platelet factor 4 antibodies are associated with arterial and venous thrombosis in patients with maintenance haemodialysis. Tan Y; Cao L; Lv JC; Yan Y; Zuo L; Wang M; Yu L; Yu F; Zhao MH Thromb Haemost; 2009 Dec; 102(6):1282-4. PubMed ID: 19967164 [No Abstract] [Full Text] [Related]
10. Antibodies to heparin-platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin-induced thrombocytopenia in hemodialysis. Davenport A Am J Kidney Dis; 2009 Aug; 54(2):361-74. PubMed ID: 19481318 [No Abstract] [Full Text] [Related]
11. Outcome of patients with positive heparin-platelet factor-4 antibodies: A retrospective multi-institutional observational study. Tapan U; Bolla S; Daglilar ES; Chang S; Kozyreva O Platelets; 2015; 26(7):661-4. PubMed ID: 25383658 [TBL] [Abstract][Full Text] [Related]
12. Anti-heparin-platelet factor 4 antibody is a risk factor for vascular access obstruction in patients undergoing hemodialysis. Lee EY; Hwang KY; Yang JO; Hong SY J Korean Med Sci; 2003 Feb; 18(1):69-72. PubMed ID: 12589090 [TBL] [Abstract][Full Text] [Related]
14. Incidence of antiheparin-platelet factor 4 antibodies and heparin-induced thrombocytopenia in Turkish patients undergoing cardiac surgery. Demir M; Duran E; Yigitbasi O; Vural O; Kurum T; Yuksel M; Turgut B; Walenga JM; Fareed J Clin Appl Thromb Hemost; 2007 Jul; 13(3):279-84. PubMed ID: 17636189 [TBL] [Abstract][Full Text] [Related]
15. Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin. Adiguzel C; Bansal V; Litinas E; Cunanan J; Iqbal O; Nelson K; Kannan M; Hoppensteadt D; Fareed J Clin Appl Thromb Hemost; 2009; 15(2):145-51. PubMed ID: 19357103 [TBL] [Abstract][Full Text] [Related]
16. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Greinacher A; Pötzsch B; Amiral J; Dummel V; Eichner A; Mueller-Eckhardt C Thromb Haemost; 1994 Feb; 71(2):247-51. PubMed ID: 8191407 [TBL] [Abstract][Full Text] [Related]
17. Prevalence of heparin-induced antibody in African-American hemodialysis patients--comparison to non-dialysis patients. Benjamin J; Moldavsky S; Lee J; Rubin R Clin Nephrol; 2009 Mar; 71(3):263-6. PubMed ID: 19281736 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of circuit and AV fistula clotting and detection of anti-PF4/heparin complex antibodies in hemodialysis patients suspected of having heparin-induced thrombocytopenia. Matsuo T; Wanaka K; Walenga JM Clin Appl Thromb Hemost; 2013; 19(1):73-8. PubMed ID: 22345486 [TBL] [Abstract][Full Text] [Related]
19. More on: thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. Alberio L; Lämmle B J Thromb Haemost; 2005 Jul; 3(7):1549. PubMed ID: 15978122 [No Abstract] [Full Text] [Related]
20. Incidence of heparin-induced thrombocytopenia and therapeutic strategies in pediatric cardiac surgery. Böning A; Morschheuser T; Bläse U; Scheewe J; von der Brelie M; Grabitz R; Cremer JT Ann Thorac Surg; 2005 Jan; 79(1):62-5. PubMed ID: 15620916 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]